ImmunologybioRxiv
Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, Against SARS-CoV-2 Challenge in Nonhuman Primates
M. Awasthi, A. Macaluso, D. Myscofski…·S. Lederman
This study evaluates the immunogenicity and efficacy of TNX-1800, a poxvirus vaccine expressing SARS-CoV-2 spike protein, in nonhuman primates challenged with SARS-CoV-2.
DOI 10.3390/vaccines11111682